DRW Securities LLC Makes New Investment in Pfizer Inc. (NYSE:PFE)

DRW Securities LLC acquired a new position in Pfizer Inc. (NYSE:PFE) in the fourth quarter, HoldingsChannel.com reports. The institutional investor acquired 33,096 shares of the biopharmaceutical company’s stock, valued at approximately $877,000.

Other institutional investors have also added to or reduced their stakes in the company. Retirement Wealth Solutions LLC bought a new position in shares of Pfizer during the fourth quarter valued at $26,000. Rialto Wealth Management LLC purchased a new stake in shares of Pfizer during the fourth quarter valued at $26,000. Kohmann Bosshard Financial Services LLC purchased a new stake in shares of Pfizer during the fourth quarter valued at $28,000. Noble Wealth Management PBC purchased a new stake in shares of Pfizer during the fourth quarter valued at $31,000. Finally, Bernard Wealth Management Corp. purchased a new stake in shares of Pfizer during the fourth quarter valued at $33,000. Institutional investors own 68.36% of the company’s stock.

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the business’s stock in a transaction on Thursday, February 13th. The stock was bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on PFE shares. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. UBS Group dropped their target price on Pfizer from $28.00 to $24.00 and set a “neutral” rating on the stock in a research report on Tuesday. The Goldman Sachs Group reissued a “neutral” rating and issued a $25.00 target price (down from $32.00) on shares of Pfizer in a research report on Tuesday. Citigroup reissued a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. Finally, Truist Financial dropped their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $31.07.

Pfizer Stock Performance

Shares of PFE stock opened at $22.50 on Thursday. The company has a market capitalization of $127.61 billion, a P/E ratio of 15.96, a P/E/G ratio of 0.64 and a beta of 0.67. The business’s 50 day moving average is $25.42 and its two-hundred day moving average is $26.51. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.10 earnings per share. Analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.